Presented
by

Presented by Oxford Global

Discover PLUS Pass

All Immuno Content

Bringing you the latest research in immuno-oncology, autoimmunity, therapeutic modalities and more, through a range of Speaker Interviews, Industry Insights, and Expert Opinions.

Industry Spotlight
Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma
Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.
Edited by Tom Cohen |
14 November 2023
Therapeutic Modalities
Industry Spotlight
Bispecific Antibody Format: Interview with Laura von Schantz, Chief Technology Officer, Alligator Biosciences
Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.
Edited by Tom Cohen |
02 November 2023
Therapeutic Modalities
Whitepaper
SomaScan Assay
A proteomics platform driving pioneering discoveries
27 October 2023
Therapeutic Modalities
Whitepaper
SomaSignal® Tests
Multiple clinical assessments from a single blood draw.
27 October 2023
Therapeutic Modalities
Whitepaper
SomaScan®Assay v4.1
The SomaScan Platform is a powerful tool with applications in scientific research and health and wellness.
27 October 2023
Therapeutic Modalities
Whitepaper
SomaScan Panels
Big Insights. Targeted Data. Consistent Results.
27 October 2023
Therapeutic Modalities
Whitepaper
Monitoring Cell – Attachment and Tightjunctions in the Same Assay
Nanion Technologies GmbH, Munich. University of Regensburg, Regensburg.
27 October 2023
Therapeutic Modalities
Industry Spotlight
Enfortumab Vedotin/Pembrolizumab Combo Beats Chemo in Phase III Breakthrough
The Phase III clinical trial, named EV-302/KEYNOTE-A39, has unveiled that immunotherapy can outperform chemo in urothelial bladder cancer for the first time.
Edited by Tom Cohen |
23 October 2023
Therapeutic Modalities
Industry Spotlight
Compugen: Exploring New Pathways and Combinations in Immunotherapy
Looking at new pathways for ICIs and Compugen's triple pathway hypothesis may be paving the way for next-generation cancer immunotherapy.
Edited by Tom Cohen |
09 October 2023
Therapeutic Modalities
Industry Spotlight
European Commission Approves Genmab’s Subcutaneous Bispecific Antibody Tepkinly
The approval follows positive results from Genmab's 'Epcore' phase I/II clinical trial.
Edited by Tom Cohen |
26 September 2023
Therapeutic Modalities

Search by Keyword

Filter by Subject Area

Immuno Series – Subject

Filter by Content Type

Resource Formats (incl. Industry Spotlight)

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Twitter Linkedin-in

Event Series

About

Careers

Legal

Copyright Oxford Global Marketing Limited. All rights reserved.